Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial (Q33402830)

26 July 2017

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial (English)

1 reference

26 July 2017

phase II clinical trial

0 references

ipilimumab

0 references

author

Pier Francesco Ferrucci

5

Pier Francesco Ferrucci

1 reference

26 July 2017

Paola Queirolo

13

0 references

Michele Maio

Michele Maio

17

0 references

Mario Santinami

Mario Santinami

4

0 references

Licia Rivoltini

Licia Rivoltini

8

0 references

Diana Giannarelli

Diana Giannarelli

6

0 references

Paolo Antonio Ascierto

2

Paolo A Ascierto

1 reference

26 July 2017

9

Ester Simeone

1 reference

26 July 2017

Anna Maria Di Giacomo

1

1 reference

26 July 2017

Lorenzo Pilla

3

1 reference

26 July 2017

Antonella Marasco

7

1 reference

26 July 2017

Stefania Vl Nicoletti

10

1 reference

26 July 2017

Ester Fonsatti

11

1 reference

26 July 2017

Diego Annesi

12

1 reference

26 July 2017

Alessandro Testori

14

1 reference

26 July 2017

Ruggero Ridolfi

15

1 reference

26 July 2017

Giorgio Parmiani

16

1 reference

26 July 2017

13 August 2012

1 reference

Lancet Oncology Commission

26 July 2017

1 reference

26 July 2017

13

1 reference

26 July 2017

9

1 reference

26 July 2017

879-886

1 reference

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Current systemic therapy for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Systematic review of medical treatment in melanoma: current status and future prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Fotemustine for the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Persistent thrombocytopenia during melanoma treatment with fotemustine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970324-8

7 January 2021

10.1016/S1470-2045(12)70324-8

Identifiers

DOI

1 reference

26 July 2017

1 reference